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Abstract
Various dermatological conditions have been reported during 
tumor necrosis factor (TNF)-a-blocking therapy, but until now no 
prospective studies have been focused on this aspect. The 
present study was set up to investigate the number and nature 
of clinically important dermatological conditions during TNF-a- 
blocking therapy in patients with rheumatoid arthritis (RA). RA 
patients starting on TNF-a-blocking therapy were prospectively 
followed up. The numbers and natures of dermatological events 
giving rise to a dermatological consultation were recorded. The 
patients w ith a dermatological event were compared with a 
group of prospectively followed up RA control patients, naive to 
TNF-a-blocking therapy and matched for follow-up period. 289 
RA patients started TNF-a-blocking therapy. 128 
dermatological events were recorded in 72 patients (25%) 
during 911 patient-years of follow-up. TNF-a-blocking therapy 
was stopped in 19 (26%) of these 72 patients because of the
dermatological event. More of the RA patients given TNF-a- 
blocking therapy (25%) than of the anti-TNF-a-naive patients 
(13%) visited a dermatologist during follow-up (P <  0.0005). 
Events were recorded more often during active treatment (0.16 
events per patient-year) than during the period of w ithdrawal of 
TNF-a-blocking therapy (0.09 events per patient-year, P  <
0.0005). The events recorded most frequently were skin 
infections (n =  33), eczema (n =  20), and drug-related eruptions 
(n =  15). Other events with a possible relation to TNF-a- 
blocking therapy included vasculitis, psoriasis, drug-induced 
systemic lupus erythematosus, dermatomyositis, and a 
lymphomatoid-papulosis-like eruption. This study is the first 
large prospective study focusing on dermatological conditions 
during TNF-a-blocking therapy. It shows that dermatological 
conditions are a significant and clinically important problem in 
RA patients receiving TNF-a-blocking therapy.
Introduction
The introduction of biological agents such as TNF-a-blocking 
agents has dramatically changed the therapeutic approach to 
rheumatic diseases in recent years. TNF-a-blocking therapy 
has had a remarkable effect on disease activity in an increas­
ing number of rheumatic diseases, including rheumatoid arthri­
tis (RA) [1-3], juvenile id iopathic arthritis [4], ankylosing 
spondylitis [5,6], and psoriatic arthritis [7]. A t present, two 
monoclonal anti-TNF-a antibodies (infliximab and adalimumab) 
and one soluble p75 TNF-a receptor (etanercept) are being 
used in rheumatological practice.
Various skin conditions have been reported in clinical trials, 
including urticaria, rash, and stom atitis (during infliximab ther­
apy) [8]; rash and injection-site reactions (during adalimumab 
therapy) [3,9]; and injection-site reactions (during etanercept 
therapy) [2].
However, clinical trials are not designed to provide information 
about the occurrence of rare adverse events associated with 
TNF-a-blocking therapy. More severe cutaneous reactions, 
such as erythema multiforme, discoid and subacute cutaneous 
lupus erythematosus, atop ic dermatitis, necrotizing vasculitis, 
and bullous skin lesions, have been reported, mostly as s ingle­
case observations [10-15]. Larger observational studies such
CI =  confidence interval; DAS28 =  disease activity score including 28-joint counts; DMARD =  disease-modifying antirheumatic drug; ELISA =  
enzyme-linked immunosorbent assay; pt-yr =  patient-year; RA =  rheumatoid arthritis; Th1/Th2 =  T helper cell type 1/2; TNF =  tumor necrosis factor. R666
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as biological registries are needed to provide information on 
the nature and number of such derm atological adverse events 
during TNF-a-blocking therapy.
The aim of this study was to investigate whether derm atologi­
cal conditions after TNF-a-blocking therapy are a significant 
and clinically important problem in RA patients receiving TNF- 
a-b locking therapy.
Materials and methods
Study design
In a prospective cohort study, all consecutive patients w ith a 
diagnosis of RA according to the criteria of the American 
Rheumatism Association [16] who were starting on TNF-a- 
blocking therapy at the Department O f Rheumatology of the 
Radboud University Nijmegen Medical Centre were followed 
as part of a Bio logical Registry [1 7]. Approval was obtained by 
the hospital's eth ics committee.
Patients were required to meet the criteria set out in the Dutch 
guidelines fo r biological therapies: a moderate to high disease 
activity score (DAS) based on 28 jo ints (D A S28 > 3.2), and 
failure or intolerability of at least tw o disease-modifying 
antirheumatic drugs (DMARDs), including methotrexate, in 
adequate dosage regimens. Besides therapy w ith registrated 
TNF-a-blocking agents -  infliximab, etanercept, and adalimu­
mab -  some patients were treated in clinical trials w ith lener- 
cept, a soluble p55 TNF-a-receptor [18].
The number and nature of derm atological conditions that led 
patients in this cohort to consult a derm atologist during follow- 
up were investigated. The RA patients treated w ith TNA-a- 
blocking agents who experienced derm atological events was 
compared w ith a contro l group of patients who had RA but 
had never had TNF-a-blocking therapy. The contro l patients 
were selected from the Nijmegen inception cohort, in which 
500 RA patients have been fo llowed since 1985 [19]. Each 
contro l was paired w ith a TNF-a-treated patient for duration 
and season of the fo llow -up period, within a 2-month w indow.
Variables
Data collected at the start of TNF-a-blocking therapy were 
age, sex, duration of disease, presence or absence of rheuma­
toid factor (measured by ELISA; considered positive if results 
showed > 1 0  IU/ml), antinuclear antibody (tested for by 
immunofluorescence on Hep-2 cells), number of DMARDs 
previously used, and start date of TNF-a-blocking therapy. 
Baseline information obtained included erythrocyte sedim en­
tation rate (ESR), 28-jo int counts for swelling and tenderness, 
and general wellbeing as indicated on a visual analogue scale, 
and the disease activity score (DAS28) was calculated [20].
Variables about which information was collected during TNF- 
a-b locking therapy were the use of concom itant DM ARDs and 
prednisolone, dose and interval changes of TNF-a-blocking
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agents and, if appropriate, date and reason for 
discontinuation.
All patients who visited a derm atologist during follow-up were 
identified. Clinically important derm atological events were 
defined as any new manifestation or any exacerbation of pre­
existing skin disease during follow-up. A  standardized chart 
review form was used to record the fo llow ing: start date of 
event, derm atological history, medication, m orphological 
description, localization, histopathological and immunohisto- 
logical information if available, working diagnosis, additional 
investigations, top ical and system ic therapeutic actions, out­
come of event, and any available information on rechallenge.
Drug-related eruptions were defined as skin reactions w ith a 
probable or definite relation to the use of TNF-a-blocking 
agents, based on a time relation w ith the administration of the 
agent, m orphological pattern, and/or histological information. 
Drug-related eruptions were classified m orphologically 
according to the criteria of Fitzpatrick and colleagues [21]. 
Events were also classified as major or minor, major events 
being any requiring hospitalization.
Patient-years of fo llow -up were calculated for total follow-up, 
time on active therapy, and time after discontinuation of ther­
apy (time off therapy). The number of events per year of follow- 
up was calculated fo r each RA patient for total time of fo llow- 
up, time on active treatment, and time off treatment, if 
appropriate.
In the contro l group, the fo llow ing baseline characteristics 
were collected: age, sex, disease duration, rheumatoid factor, 
antinuclear antibody, DAS28, the number of DMARDs previ­
ously used, and prednisolone use. All visits to a derm atologist 
during fo llow -up were identified. Events were not recorded in 
the contro l group.
Statistical analyses
The baseline characteristics of RA patients on TNF-a-blocking 
therapy were compared according to whether or not the 
patients experienced derm atological events. The chi-square 
test was applied for d ichotom ous variables and S tudent's t - 
test was used for continuous variables. Nonparam etric tests 
were applied when appropriate. The W ilcoxon signed rank test 
was used to compare the number of events per patient-year of 
follow-up in patients receiving and patients not receiving 
active TNF-a-blocking therapy. Univariate and multivariate 
logistic regression analyses were performed to identify possi­
ble predictive factors for the occurrence of a dermatological 
visit (independent variable, dichotom ous) in RA patients on 
TNF-a-blocking therapy. Dependent variables tested were 
sex, age at diagnosis, rheumatoid factor, antinuclear antibody, 
disease duration, D A S 28 at baseline, prior number of 
DMARDs, use of prednisolone, and duration of follow-up.
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Table  1
Base line  cha racte ris tics  o f pa tie n ts  w ith  rheum a to id  a rth r it is  (RA) s tud ied
Given TNF-a-blocking therapy Controlsa
Characteristic All patients N  =  289 Patients with dermatological 
events N  =  72
N  =  289
Male sex, no. (%) 89 (31) 20 (28) 110 (38)
Age (yr) at diagnosis, mean (SD) 44.5 (14.7) 43.4 (12.7) 54.6 (14.1)**
RF-positive, no. (%) 249 (87) 68 (94) 205 (71)*
Disease duration (yr) at baseline, median (range) 9.2 (0.1-44.9) 10.3 (0.3-44.9)+ 6.2 (0.0-12.6)**
DAS28 at baseline, mean (SD) 5.9 (1.1) 6.1 (1.1) 3.6 (1.4)**
ANA-positive at baseline, no. (%)b 112 (50) 33 (49) 118 (41)
Prior DMARDs, median (range) 4 (1-10) 5 (2-8) 1 (0-6)**
Prednisolone at baseline, no. (%) 112 (39) 34 (47) 21 (7)**
aNot given TNF-a-blocking therapy. bANA at start was present in respectively 261 and 67 patients on TNF-a-blocking therapy. *P <  0.001, **P <  
0.0001, compared with RA patients on TNF-a-blocking therapy; fP  <  0.001 compared with RA patients on TNF-a-blocking therapy who 
experienced no dermatological events. ANA, antinuclear antibody; DAS28, disease activity score based on 28 joints; DMARD, disease-modifying 
antirheumatic drug; RF, rheumatoid factor; SD, standard deviation; TNF, tumor necrosis factor.
O dds ratios (ORs) and 95%  confidence intervals (95%  CIs) 
were calculated.
The number of patients who visited a derm atologist was com ­
pared between RA patients on TNF-a-blocking therapy and 
controls, using the chi-square test. P  values and ORs were 
calculated.
All tests were two-sided, w ith P  <  0 .05 considered statistically 
significant. Statistical analyses were performed using SPSS 
statistical software (v 12.0.1, SPSS Inc, USA).
receiving gold (7), nonsteroidal anti-inflammatory drugs (2), or 
methotrexate (1) -  10 cases of eczema, 9 of mycosis, 3 of 
other infections, and 5 of chronic venous insufficiency.
Predictive factors
In univariate analyses, duration of fo llow -up (OR 1.27, 95% C I 
1.14 to 1.41, P  <  0 .0005) and of disease (OR 1.03, 95% C I 
1.003 to 1.07, P  <  0.05) were statistically significant p red ic­
tive factors for a derm atological event. In a multivariate model, 
only duration of fo llow-up was a statistically significant pred ic­
tive factor (OR 1.30, 95% C I 1.12 to 1.52, P  <  0.001).
Results
Patients
A total of 289 RA patients started TNF-a-blocking therapy 
between June 1994 and Decem ber 2003. Their baseline char­
acteristics are shown in Table 1.
The median fo llow -up time was 2.3 years (range 0.02 to 9.6). 
The total follow-up time was 911 patient-years, w ith 627 
patient-years representing active therapy. Seventy of the 289 
RA patients (24% ) received more than one TNF-a-blocking 
agent and 8 (3%) received more than two agents. Infliximab 
was adm inistered to 167 patients, adalimumab to 108, etaner­
cept to 78, and lenercept to 31.
Dermatological events were recorded in 72 of the 289 RA 
patients (25% ) receiving TNF-a-blocking therapy and in 37 
(13% ) of the contro l group (n =  289). The odds ratio (OR) of 
TNF-a-blocking therapy for a derm atological referral was 2.26 
(95% CI 1.46 to 3.50, P  <  0 .0005). In patients on TNF-a- 
blocking therapy fifty-six instances of derm atological cond i­
tions were recorded in 34 patients (47% ) and included, 
among others, 10 drug reactions -  while the patient was
Dermatological events
One hundred and twenty-eight derm atological events were 
recorded during fo llow -up in RA patients on TNF-a-blocking 
therapy (0.14 event per patient-year), as listed in Table 2 . The 
event per patient-year ratio was 0.16 during active treatment 
and 0.10 off treatm ent (P  <  0.001). The number of events 
recorded during or after treatm ent was 56 fo r adalimumab 
(0.12 event per patient-year), 49 for infliximab (0.14 per 
patient-year), 16 fo r etanercept (0.13 per patient-year), and 13 
for lenercept (0.07 per patient-year). TNF-a-blocking therapy 
was permanently w ithdrawn because of derm atological events 
21 times in 19 patients.
Infections
Thirty-three infections were recorded in 27 patients, consist­
ing of 20 fungal, 11 bacterial, and 2 viral infections (see Table 
3). Two patients had had a previous episode of 
dermatomycosis. None of the patients required hospitalization. 
One patient, who temporarily discontinued adalimumab m on­
otherapy tw ice  because of elective surgery, developed a bac­
terial superinfection of pre-existing eczema after every restart.
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Table  2
D e rm ato log ica l events in pa tie n ts  w ith  rheum a to id  a rth r it is  (RA) g iven TN F-a -b lock ing  the rapy
Nature of event Events Time to event (months) Events during 
treatment
Major events Histology DM A RDsb Prednisoloneb Permanent 
withdrawal of anti- 
TNF-ac
No. (%) Mediana Range No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Infection 3 3  (25.8) 9.1 1 .1 -61 .1 24 (73) 0 5 (15) 20  (61) 21 (64) 4 (12)
Eczema 20 (15.6) 7.1 0 .2 -4 9 .9 16 (80) 1 (5) 4 (20) 8 (40) 7 (35) 3 (15)
Drug-related eruption 15 (11.7) 1.9 0 .1 -1 8 .8 15 (100) 1 (7) 12 (80) 6 (40) 6 (40) 7 47)
Ulcers 9 (7.0) 13.6 0 .3 -5 2 .5 3 (33) 1 (11 ) 2 (22 ) 7 (78) 4 (44) 1 (11 )
Skin tumor, benign 7 (5.5) 12.9 2 .0 -18 .1 7 (100) 0 2 (29) 5 (71) 4 (57) 0
Skin tumor, malignant 5 (3.9) 4.5 1 .1 -3 8 .0 4 (80) 0 5 (100) 2 (40) 2 (40) 1 (20 )
Xerosis cutis 6 (4.7) 8.9 4 .2 -2 6 .3 6 (10 0 ) 0 1 (16) 4 (67) 1 (17) 1 (17)
Vasculitis 5 (3.9) 12.0 1 .5 -4 9 .9 4 (80) 0 4 (80) 3 (60) 5 (100) 1 (20 )
Actinic keratosis 5 (3.9) 26.3 4 .5 -1 1 2 .9 2 (40) 0 3 (60) 5 (100) 2 (40) 0
CVI/varices 4 (3.0) 24.0 1 .7 -3 3 .6 3 (75) 0 0 3 (75) 2 (50) 0
Psoriasis/
psoriasiform
3 (2.3) 15.5 8 .4 -5 0 .1 3 (100) 0 3 (100) 0 2 (67) 1 (33)
Edema 3 (2.2) 8.2 4 .0 -3 9 .6 2 (67) 0 1 (33) 1 (33) 1 (33) 0
Stasis dermatitis 3 (2.2) 17.5 1 4 .6 -42 .1 3 (100) 0 1 (33) 1 (33) 1 (33) 0
Seborrheic dermatitis 2 (1.5) 0.4, 19.8 - 2 ( 1 00 ) 0 0 0 0 0
O ther event 8 (6.0) 5.0 1 .9 -2 5 .9 6 (75) 0 4 (50) 4 (50) 2 (25) 2 (25)
Total 128 (1 00 ) 9.1 0 .1 -1 1 2 .9 100 (78) 3 (2) 4 7  (37) 69  (54) 60  (47) 21 (16)
aMedian and range given for three cases or more; individual data given for two cases or fewer. bNumber of patients with concomitant DMARDs and 
prednisolone at the time of event. cPermanent discontinuation of TNF-a-blocking therapy because of the event. DMARD, disease-modifying anti­
rheumatic drug; TNF, tumor necrosis factor.
Eczema
Eczema was diagnosed 20 times in 19 patients and appeared 
in various m orphological patterns. Most events were 
described as erythematosquamous (n =  8) or erythematous (n 
=  3) lesions or plaques, localized on hands and feet (n =  3), 
arms and legs (n =  5), face (n =  1), neck (n =  1), and buttocks 
(n =  1). A  vesicular rash on hands and feet was described five 
times. A  papular rash was described in three cases, w ith local­
ization around the eyes, on the back, and once on the back and 
lower legs. D iagnoses com prised dyshidrotic (n =  5), contact 
(n =  4), nummular (n =  1), atop ic (n =  1), papular (n =  1), and 
nonspecific eczema (n =  8). Two patients had a prior history 
of dyshidrotic eczema.
Biopsies were performed in five events. H isto logy showed der­
matitis and spongiosis in all cases, w ith high dermal perivascu­
lar infiltration in three. One biopsy also showed mild 
psoriasiform acanthosis and another showed additional kerat- 
inocyte necrosis.
Three patients stopped TNF-a-blocking therapy because of 
the derm atological event, after which the lesions resolved. 
Hospitalization was necessary for treatm ent of eczema in one 
patient. In another patient the eczematous lesions recurred
after adalimumab therapy was restarted. Adalimum ab was 
continued and top ical steroids were applied w ith good effect. 
TNF-a-blocking therapy had already been stopped in 4 
patients before the onset of eczema and was continued in 13 
patients, of whom 7 had persisting or recurring lesions. Ther­
apy consisted mostly of top ical corticosteroids.
Drug-related eruptions
Drug-related eruptions occurred frequently during the first 5 
months of TNF-a-blocking therapy and were caused by all four 
TNF-a-blocking agents (see Table 4 ). In tw o cases, a general­
ized drug-related eruption followed subcutaneous injection of 
etanercept. In two cases, the eruption developed during infu­
sion (patients numbers 8 and 11, Table 4 ). In the other cases 
the time of onset ranged between 2 and 57 days after the 
most recent infusion.
Most drug-related eruptions consisted of a com bination of 
m orphological patterns, including exanthema, urticarial erup­
tions, lichenoid skin lesions, and purpura. In four patients, an 
eczematous drug-related eruption was seen. Classification as 
drug-related eruption was based on a time relation w ith adm in­
istration of the TNF-a-blocking agent, the m orphological pat­
tern, and/or histological information. Two patients had
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Table  3
S k in  in fe c tio ns  in pa tie n ts  w ith  rheum a to id  a rth r it is  (RA) g iven TN F-a -b lock ing  the rapy
Time to event
Infection No. of events Median Range Druga (no.) Active treatmentb 
(no.)
Rechallenge
(no.)
Permanent 
withdrawal of anti- 
TN F-ac (no.)
Biopsy
(no.)
Cultured species
Fungal 20 8.7 1 .1 -61 .1
Dermatomycosis 9 A 3, I 4, E 2 7 0 1 Trichophyton 
verrucosum (1) T. 
rubrum (1)
Onychomycosis 3 A 3 3 0 0
Combination 5 A 3, I 1, L 1 4 0 1 Trichophyton 
rubrum (3) T. 
mentagrofytes (1)
Candidiasis 3 I 3 2 0 0 Candida spp. (2)
B acteria l 11 9.5 1 .4 -5 2 .5
Folliculitis 5 A 3, E 2 4 yes, negative 1 2 Staphylococcus 
aureus (1)
Erysipelas 3 E 2, I 1 3 yes, negative 2 1
Bacterial 
superinfection of 
eczema
2 A 1, I 1 1 yes, positive 1 0
Furuncle 1 I 1 0 0 0
Viral -  herpes zoster 2 17.3, 4 0 .9 d A 1, I 1 0 0 0
aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bDuring active treatment with TNF-a-blocking therapy. cPermanent discontinuation of TNF- 
a-blocking therapy due to the event.d Individual values
experienced a previous drug-induced eruption (1 derm atitis in 
response to gold, 1 derm atitis after indomethacin).
The histological find ings were com patible w ith the diagnosis in 
all cases. Perivascular infiltrations -  predominantly lym­
phocytic -  epidermal exocytosis, and hyperorthokeratosis 
were described. Interface dermatitis was described in three 
instances. One biopsy revealed focal infiltrations w ith marked 
vascular and endothelial proliferation.
Seven patients s topped and 8 patients continued therapy; 6 
of them had a positive rechallenge and recurring lesions. One 
major event was recorded: an RA patient was hospitalized for 
an extensive eczematous eruption w ith urticaria on arms and 
legs (Fig. 1, and Patient no. 6 in Table 4 ). Treatment consisted 
mostly of top ical application of corticostero ids and sometimes 
of system ic antihistamines.
squamous cell carcinoma (earlobe) after 1.5 months of adali- 
mumab therapy and a low-grade basalioma (Pinkus epitheli­
oma) on the leg after 6 months of adalimumab therapy. In all 
cases, histology confirmed the diagnosis and therapy con­
sisted of excision. No recurrences were seen.
A ctin ic  keratosis was recorded in five patients (three receiving 
adalimumab, one infliximab, and one lenercept). Excision or 
cryotherapy was successful in four. One patient had recurring 
actin ic lesions on the scalp.
Benign tumors were recorded seven times during TNF-a- 
blocking therapy. One patient experienced an increased 
growth of a facial te langiectatic nevus, present since ch ild­
hood, 2 months after starting etanercept therapy. Seborrheic 
keratosis (n =  3), oral hyperkeratosis (n =  1), histiocytom a (n 
=  1), and fibrom a (n =  1) were also recorded.
Tumors and actinic keratosis
Events of skin malignancies were recorded five times, in four 
patients. One RA patient developed three basal cell carcino­
mas simultaneously on her left arm, right nostril, and right eye­
lid after 2.7 years of adalimumab therapy, which was 
subsequently stopped. One 74-year-old RA patient developed 
Bowen's disease on his right hand 2 years after adalimumab 
therapy had been stopped. The same patient later developed 
a squamous cell carcinoma on the left earlobe after the start of 
etanercept therapy. O ther skin malignancies recorded were a
Vasculitis
Vasculitis was recorded five times: four during and one after 
cessation of TNF-a-blocking therapy. The diagnosis was con­
firmed by biopsy in four cases. One patient developed a super­
ficial necrotizing leukocytoclastic vasculitis w ith ulceration 
after 7 months of infliximab therapy, w ith com plete recovery 
after discontinuation of infliximab. One patient developed a 
papular erythema in the groins after 5 years of adalimumab 
therapy. H isto logical examination was com patible w ith vascu­
litis w ith infiltration of m ononuclear cells and presence of eosi-
R670
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Table  4
D rug-re la ted  sk in  e ru p tio n s  in pa tien ts  w ith  rheum a to id  a rth r it is  (RA) g iven TN F-a -b lock ing  therapy
Patient
no.
Age
(yr)
Sex Druga Route Type of eruption Clinical
description
Localization Time to 
event
(mo)
Biopsy Comedicationb Therapy Rechallenge Permanent Course 
withdrawal 
of anti- 
TN F-a
1 62 f A i.v. Eczematous Erythematosq 
uamous 
plaques and 
papules
Neck/
axillary/
legs
4.5 Yes naproxen Local positive No Recurring
2 71 m A i.v. Exanthematous
lichenoid
Maculopapula 
r exanthema
Generalized 0.7 Yes prednisolone,
naproxen,
paracetamol
Local positive Yes Recovery
3 77 m E s.c. Exanthematous Macular
exanthema
Generalized 6.8 Yes prednisolone,
naproxen,
omeprazole
Local positive No Recurring
4 67 m E s.c. Lichenoid Macular
exanthema,
purpura
Generalized 1.5 Yes diclofenac,
omeprazole,
triamterene,
furosemide,
candesartan
Topical,
systemic
No Yes Recovery
5 69 f I i.v. Eczematous Erythematous
plaque
Right cheek 0.1 Yes MTX, pantoprazole, Topical 
atenolol, calcium, 
hydrochlorothiazi 
de
positive No Recurring
6 88 f I i.v. Eczematous
urticarial
Erythematosq
uamous
macula,
purpura
Lower
arms/legs
3.9 Yes leflunomide,
carbasalate
calcium,
omeprazole,
furosemide,
simvastatin,
paracetamol
Topical No Yes Recovery
7 68 f I i.v. Eczematous
urticarial
Erythematosq 
uamous 
plaques, 
urticaria, 
excoriations, 
lichenificatio 
n, purpura
Generalized 10.3 No AZA, furosemide, 
oxazepam, 
enalapril, 
spironolactone, 
metoprolol, 
flixotide, 
formoterol
Topical,
systemic
negative No Recovery
8 60 f I i.v. Exanthematous Stippled
exanthema
Generalized 0.5 Yes naproxen,
omeprazole
Topical No Yes Recovery
9 53 f I i.v. Exanthematous Exanthema Upper
arms/legs
0.2 No indomethacin Topical positive No Recurring
10 73 f I i.v. Exanthematous, 
with purpura
Exanthema,
purpura
Lower legs 18.8 No MTX, folic acid, 
prednisolone, 
morphine, 
loperamide, 
latanoprost
Topical No Yes Recovery
11 70 f I i.v. Exanthematous
urticarial
Exanthema,
urticaria
Arms/ trunk 16.6 Yes leflunomide None positive No Recurring
12 35 f I i.v. Exanthematous 
urticarial, with 
purpura
Macular
exanthema,
uricaria,
purpura
Trunk/
axillary/
groins
1.9 Yes none Topical Yes Recovery
13 58 f I i.v. Lichenoid Erythema,
hyperpigme
ntation,
atrophy
Upper legs 15.5 Yes leflunomide,
meloxicam,
metoclopramide,
acenocoumarol,
digoxin
None No Yes Recovery
14 58 f L i.v. Exanthematous Papular
exanthema
Generalized 0.4 Yes none Topical positive No Recurring
15 68 m L i.v. Exanthematous
lichenoid
Maculopapula 
r exanthema
Generalized 1.7 Yes prednisolone,
paracetamol
Topical negative No Recovery
Events numbers 5 and 11 occurred in the same patient, as did events numbers 2, 3, and 15. aA, adalimumab; Age =  age ar event; I, infliximab; E, 
etanercept; L, lenercept. bMTX, methotrexate; AZA, azathioprine. f, female; i.v., intravenous; m, male; s.c., subcutaneous.
nophilic granulocytes. O ne patient developed a purpuric improving spontaneously despite continuation of lenercept. 
vasculitis on the legs after 1.5 months of lenercept therapy, One patient developed isolated digital vasculitis on his toes
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F igure  1
Eczematous drug-relatederuptiona patient with rheumatoid arthritis after infliximab therapy:Eczematouseruptions on the left arm (top left) and right 
arm (top right) and erythematous eruptions with purpura on the left leg (bottom left) and right leg (bottom right).
after one year of adalimumab therapy, which was continued. 
The lesions persisted. No biopsy was performed. One patient 
developed a generalized urticarial exanthema after therapy 
w ith etanercept 2 years earlier. Current therapy consisted of 
hydroxychloroquine and prednisolone. H isto logy showed a 
mild leukocytoclastic vasculitis.
Ulcers
The nine events w ith ulcers included four pressure ulcers, two 
ulcers due to dependency edema, one traumatic ulcer, one 
ulcer secondary to an unguis incarnatus, and one ulcer w ithout 
further specification. B iopsies were taken in two patients, but 
no signs of vasculitis were found. A  patient had a pressure 
ulcer w ith secondary infection and a fistula on his ankle, which 
contained osteosynthetic material. The patient was admitted 
to the hospital for intravenous antib iotic therapy and infliximab 
was stopped for several months. A fte r recovery, the patient 
restarted infliximab w ithout recurrence of his skin problems. 
TNF-a-blocking therapy was continued in the other eight 
patients, and in four of these the ulcers recovered; follow-up 
was missing in the other four.
Stasis dermatitis, edema, varices and chronic venous 
insufficiency
In 10 patients, a derm atological consultation was recorded for 
stasis derm atitis (n =  3), edema (n =  3), varices (n =  2), or 
chronic venous insufficiency (n =  2). In one patient w ith exten­
sive varices, infliximab therapy was stopped temporarily 
because of a com plicating throm bophlebitis. One patient had 
edema of both legs of unknown cause, w ith livid discoloration 
and induration. One patient had lymphedema secondary to
RA. All other events were considered to be related to com or­
bidity, other than RA.
Psoriasis and psoriasiform eruptions
Psoriatic or psoriasiform eruptions were recorded in three RA 
patients. One developed a vesiculopustular erythematosqua- 
mous rash on hands and feet after 9 months of adalimumab 
therapy. H isto logy showed a mixed psoriasiform and spongi- 
o tic dermatitis. A  second RA patient developed psoriasis gut- 
tata-like eruptions on her lower legs after 4 years of therapy 
w ith adalimumab. The lesions dim inished after adalimumab 
was w ithdrawn. A  third patient developed a psoriasiform 
eruption on arms and legs after 16 months of adalimumab 
therapy. H isto logy obtained in the latter two patients was con­
sistent w ith psoriasis.
Other dermatological conditions
O ther derm atological conditions that occurred during or after 
TNF-a-blocking therapy included, among others, dermatomy­
ositis (1), drug-induced system ic lupus erythematosus (1 ), and 
lymphomatoid papulosis-like eruption (1). Details are shown in 
Table 5 .
One RA patient developed a macular rash on the inner sides 
of the upper arms and legs after 2.5 months of lenercept m on­
otherapy. A  skin biopsy showed a nonspecific chronic derm a­
titis. A  soft-tissue biopsy, including skin, fascia, and muscle, 
showed fascial and muscular infiltration, consistent with 
dermatomyositis.
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Table  5
O ther de rm a to lo g ica l events in pa tien ts  w ith  rheum ato id  a rth r it is  (R A) g iven TN F-a -b lock ing  the rapy
Patient
no.
Age (yr) Sex Diagnosis Druga Active
treatment
Event Clinical
description
Localization Time to 
event
Biopsy Comedicationb Permanent Therapy 
withdrawal 
anti-TN F-a
Course
1 56 f RA A Yes Lymphomatoid Macular 
papulosis- erythematos 
like eruption quamous 
lesions
Lower 
arms, 
upper 
legs and 
trunk
2.6 Yes naproxen No None Recovery
2 53 f RA A Yes Rosacea Diffuse
erythema,
scaling,
telangiectasi
as
Head and 
face
1.9 Yes prednisolone, 
captopril, 
indomethaci 
n, midazolam
No Topical Persisting
3 74 f RA E Yes Pruritus Itch Trunk 2.5 No None No Topical Unknown
4 61 f RA I No Ecchymoses Ecchymoses Hands and 
feet
25.9 No AZA,
prednisolone
No Topical Partial
recovery
5 58 f RA I Yes Drug-induced
systemic
lupus
emythemato
sus
Discoid 
erythematou 
s lesions, 
aphthous 
lesions, ANA  
positive, anti- 
ds-DNA  
positive
Hands,
face,
scalp
20.0 No MTX Yes Topical
and
systemic
Recovery, no 
rechallenge
6 68 m RA I Yes Transient 
swelling of 
unknown 
cause
Transient 
swelling 2 x  
3 cm
Scalp 20.0 No MTX, folic 
acid, 
naproxen
No None Recovery
7 52 f RA L Yes Dermatomyosit Livid erythema, 
is raised CPK, 
decreased  
proximal 
muscular 
strength
Inner upper 
arms and 
legs
2.5 Yes None Yes None Recovery
8 53 m RA L No Erythema
nodosum
Painful 
erythematou 
s nodules
Lower legs 7.4 Yes AZA,
naproxen,
paracetamol
No Topical Partial
recovery
aA, adalimumab; I, infliximab; E, etanercept; L, lenercept. bMTX, methotrexate; AZA, azathioprine. CPK, creatinine phosphokinase; f, female, m, male.
One RA patient developed a drug-induced system ic lupus ery­
thematosus after 20 months of infliximab therapy in com bina­
tion w ith methotrexate, consisting of d iscoid lupus 
erythematosus lesions on her hands and scalp, aphthous 
lesions, conversion to antinuclear antibody positivity, and a 
positive anti-double stranded-DNA (titer 60 U/L). The skin 
lesions flared within one week after infusion and disappeared 
after discontinuation of infliximab.
A  third RA patient developed macular erythematosquamous 
lesions on her lower arms, upper legs and trunk after 2.6 
months of adalimumab monotherapy. H isto logy showed a der­
mal infiltration w ith CD 30-positive atypical T cells. A lthough 
the lesions appeared to be lymphomatoid papulosis, they com ­
pletely disappeared within 6 weeks. Adalimumab was not 
stopped. This patient developed a large-cell anaplastic non- 
Hodgkin lymphoma 2 years later.
Discussion
The present study is the first large prospective study focusing 
on derm atological conditions in RA patients on TNF-a-block-
ing therapy. O f the patients studied, 25%  needed a derm ato­
logical consultation, com pared w ith 13%  in a RA control 
group, naive to TNF-a-blocking therapy. The number of 
derm atological events per patient-year was significantly higher 
during treatm ent than after treatm ent w ith TNF-a-blocking 
therapy. Derm atological events led to w ithdrawal of TNF-a- 
blocking therapy in 19 patients of 72 patients (26% ). The 
events recorded most frequently were skin infections, eczema, 
and drug-related eruptions. Some other interesting events 
were recorded, such as psoriasis, drug-induced systemic 
lupus erythematosus, dermatomyositis, and a lymphomatoid- 
papulosis like eruption.
RA is known to be associated w ith derm atological conditions 
such as vasculitis, nodulosis, palmar erythema, and bullous 
pemphigoid, among others [22,23]. A t present, information on 
the incidence and prevalence of derm atological conditions in 
RA mainly originates from cross-sectional or retrospective 
studies [24-26]. Few prospective studies have been con­
ducted focusing on specific  conditions affecting the skin 
[27,28].
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In establishing a relation between the use of a drug and the 
occurrence of derm atological conditions, various factors must 
be considered. Information on clinical and histological pat­
terns, time and dose relation, dechallenge and rechallenge, 
and analogy w ith previously reported cases can provide sup­
port in assessing the plausibility of such a relation [29]. The 
underlying disease and concom itant m edication also need 
careful consideration, as they can provide alternative 
explanations.
In this study the largest group of derm atological events con­
sisted of skin infections, mostly fungal infections and fo llicu li­
tis. The use of TNF-a-blocking therapy has raised concerns 
regarding an increased susceptib ility to infections, as TNF-a 
plays an important role in host-defence mechanisms [30]. An 
increased incidence of tuberculosis has been described [31], 
as well as a growing number of serious infections w ith fungal, 
mycobacterial, and intracellular bacterial pathogens [32-34]. 
Infections of the skin have not been the subject of report in 
clinical trials and observational studies w ith TNF-a-blocking 
therapy. Cases of severe necrotizing fasciitis have been 
described [35,36].
Skin infections have been reported frequently in the normal 
population and especially in RA patients [24-26]. Host- 
defence impairments resulting from the underlying disease 
m ight play a role in an increased susceptib ility to skin infec­
tions in RA patients, as well as the use of corticostero ids and 
DMARDs such as methotrexate [28,37], which were recorded 
frequently in the present study (see Table 2). They could p ro­
vide an alternative explanation for the occurrence of skin infec­
tions. However, most infections occurred during active 
treatment w ith TNF-a-blocking therapy, a finding that could 
suggest at least a relative contribution to an increased vulner­
ability to skin infections in the study population. In one patient, 
a bacterial superinfection of eczema occurred tw ice  immedi­
ately after restart of adalimumab, showing a clear time relation.
For the description of the recorded drug-related eruptions, a 
clin ico-m orphological classification was chosen [21]. Four 
eruptions w ith a time relation and clinically or histological d is­
tinct drug-induced patterns also showed an eczematous 
appearance, both clinically and histologically. This is an 
unusual presentation fo r a drug-induced eruption and warrants 
further investigation.
Two drug-related eruptions occurred during infusion w ith inf­
liximab or adalimumab, whereas all the others occurred after 
infusion. This will most likely not reflect the true ratio between 
acute and delayed reactions involving the skin, since acute 
reactions w ith skin involvement occur in 4%  of the infusions 
and are usually treated by the rheumatologist w ithout derma­
to logical consultation [38].
Eczema was reported frequently in this study, even w ith vari­
ous dermatitis conditions, such as xerosis cutis, stasis 
eczema, and seborrheic eczema, classified as separate enti­
ties. Previous studies have reported RA, in which Th 1 (T helper 
cell type 1) immune responses dominate, to be negatively 
associated w ith Th2-cell-m ediated atop ic disorders, such as 
eczema [39-41], although a similar incidence of eczema in RA 
and non-RA patients has also been reported [42]. TNF-a- 
blocking therapy down-regulates Th1 immune responses [43], 
which m ight induce a shift of the Th1/Th2 balance towards 
Th2-dom inated immune responses and which m ight promote 
an increased susceptib ility to atop ic disorders, such as 
eczema.
Although the time between the initiation of TNF-a-blocking 
therapy and the onset of derm atological conditions varied, a 
probable relation was seen in various events. These included, 
besides drug-related eruptions, events of cutaneous vasculitis, 
drug-induced system ic lupus erythematosus, dermatomyosi­
tis, and a lymphomatoid papulosis-like eruption.
An association between the use of TNF-a-blocking therapy 
and the induction of system ic lupus erythematosus and d is­
coid lupus erythematosus is strongly suggested by the 
number of cases that have been published [10 ,11,13 ,44-46 ]. 
One case of d iscoid lupus erythematosus has been described 
on both etanercept and infliximab in the same RA patient [47].
Analogy w ith previous reports is also present fo r cutaneous 
vasculitis [13 ,47-49 ], although it is a known extra-articular 
manifestation of RA [22,23]. In the first case described, a 
probable relation w ith infliximab was present, based on the 
time relation and positive dechallenge. The other cases 
described were considered possibly related (Results section, 
Vaculitis, cases 2 and 3) and unlikely (cases 4 and 5). A lm ost 
all reported ulcers were considered secondary to other 
causes, as described.
Dermatomyositis has been reported previously, although the 
patient affected in that case had a different presentation, with 
raised creatinine phosphokinase, muscle atrophy, m echanic's 
hands, and vasculitis [17].
Another interesting finding was the occurrence of psoriasiform 
eruptions in three patients on TNF-a-blocking therapy. This 
observation is particularly interesting, since etanercept has 
received and infliximab is close to receiving FDA approval fo r 
treatment of psoriasis, after remarkable efficacy results in c lin­
ical trials [7,50,51]. The occurrence of guttate psoriasis has 
been reported after initiation of etanercept therapy for psoria­
sis in a p lacebo-controlled trial [51]. Another case report 
described the occurrence of psoriasiform eruptions w ith h isto­
logically a lichenoid derm atitis pattern in a patient w ith Crohn's 
disease [52].
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An exacerbation of psoriasis was also seen in a patient w ith 
psoriatic arthritis receiving infliximab therapy. An additional 
analysis showed that 28  patients w ith various non-RA rheu­
matic diseases, including 12 juvenile id iopathic arthritis, 6 pso­
riatic arthritis, and 3 ankylosing spondylitis, had been treated 
w ith TNF-a-blocking therapy in the study centre. Five patients 
(18% ) had visited a derm atologist for a derm atological cond i­
tion during or after TNF-a-blocking therapy. The events 
included a drug-related eruption, eczema, and a facial mycosis 
in three patients w ith juvenile id iopathic arthritis and a superfi­
cial spreading melanoma in a patient w ith ankylosing spondyli­
tis. This indicates that the occurrence of derm atological events 
during TNF-a-blocking therapy is not restricted to RA patients.
In the present study the contro l patients were matched for 
sartdate and duration of fo llow-up period in order to contro l for 
time-related effects. A  statistically significant relation between 
the use of TNF-a-blocking therapy and the occurrence of der­
m atological visits was shown. The two groups studied differed 
fo r most baseline characteristics. These differences result 
from the indication fo r TNF-a-blocking agents, which were 
reserved for patients who fulfilled criteria fo r active disease 
and DMARD failure (see m ethods section; study design), had 
a longer disease duration, and whose disease was perhaps 
more refractory.
However, it is considered unlikely that these factors influenced 
the relation between the use of TNF-a-blocking therapy and 
derm atological visits. In a multivariate regression model, no 
baseline characteristic showed a predictive value for the 
occurrence of a derm atological event in RA patients on TNF- 
a-b locking therapy. Also, a statistically significantly higher 
number of derm atological events was recorded during active 
treatment w ith TNF-a-blocking therapy than after the therapy 
had been stopped.
Conclusion
This is the first prospective study showing a relation between 
TNF-a-blocking therapy and the occurrence of dermatological 
conditions. Future prospective studies are needed to investi­
gate the incidence and the pathogenesis of the encountered 
events, because they are a clinically significant problem in RA 
patients receiving TNF-a-blocking therapy.
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